Management of Irregular Vaginal Bleeding in Premenopausal Women

Assessment and Exclusion of Underlying Pathology

Prior to initiating monotherapy, clinicians should exclude pregnancy, sexually transmitted infections, thyroid dysfunction, medication interactions, and structural uterine pathology (e.g., polyps, fibroids, malignancy) using appropriate testing such as β‑hCG, STI screening, TSH measurement, medication review, and transvaginal ultrasound. 1, 2, 4

Recommendation: For premenopausal women with irregular vaginal bleeding and no contraindications to hormonal therapy, a short course of NSAIDs (5–7 days per bleeding episode) is the preferred first‑line monotherapy because it is effective across various contraceptive methods and bleeding patterns without adding hormonal complexity. Evidence quality: CDC 2024 guidelines (Consensus, Level C). 1, 2, 3
Dosing: Administer NSAIDs for 5–7 days during each bleeding episode. 1, 2, 3
Agents: Ibuprofen, mefenamic acid, or celecoxib may be used. 1, 2
Evidence support: CDC 2024 recommendations endorse NSAID use for multiple contraceptive‑related bleeding scenarios. Evidence quality: Consensus (Level C). 1, 2, 3

Dosing: Provide tranexamic acid for 5 days during each bleeding episode. 1, 2
Indication: Consider when bleeding is heavy or prolonged and NSAIDs have been insufficient. 1, 2

Dosing: Low‑dose COC regimen for 10–20 days per cycle. 1, 5, 2
Efficacy: Reduces menstrual blood loss by approximately 40–50 %. 5
Additional Benefits: Provides contraception, decreases dysmenorrhea, and lowers risk of ovarian and uterine cancers. 5
Best Use: Appropriate for women who desire contraception or who have anovulatory bleeding patterns. Evidence quality: Not explicitly graded; based on guideline consensus. 6

Dosing: Cyclic therapy administered for 21 days each month. 5
Efficacy: Produces a significant reduction in menstrual blood loss with cyclic use. 5
Best Use: Targeted toward anovulatory bleeding patterns. 6

Hormone‑Free Interval Caution: Do not introduce hormone‑free intervals during the first 21 days of extended/continuous combined hormonal contraceptive (CHC) regimens, and avoid hormone‑free intervals more than once per month, as these practices diminish contraceptive effectiveness. Evidence quality: CDC 2024 guidelines (Consensus, Level C). 1, 7, 2
When Monotherapy Fails: Re‑evaluate for missed structural pathology using saline‑infusion sonohysterography or hysteroscopy. 4

The 2024 CDC guidelines form the primary framework for managing irregular vaginal bleeding; recommendations are largely based on consensus (Level C evidence). 1, 2, 3
Systematic reviews indicate that NSAID therapy in depot‑medroxyprogesterone acetate (DMPA) users leads to significant bleeding cessation within 7 days compared with placebo. Evidence quality: Systematic review (higher‑level evidence). 5
Choice between NSAID and hormonal monotherapy should be individualized according to the patient’s desire for contraception, the underlying bleeding pattern (anovulatory vs. ovulatory), and preference for hormonal versus non‑hormonal management. 6